ProCE Banner Activity

Immunotherapy in the Management of Patients With HCC: Answers to Frequently Asked Questions

Clinical Thought

A commentary covering frequently asked questions related to the use of immunotherapy in the management of patients with hepatocellular carcinoma

Released: June 24, 2024

Expiration: June 23, 2025

Share

Faculty

Richard S. Finn

Richard S. Finn, MD

Professor
Department of Medicine
Division of Hematology/Oncology
UCLA David Geffen School of Medicine
Medical Director, Clinical Research Unit
Director, Signal Transduction and Therapeutics Program
University of California, Los Angeles
Los Angeles, California

Sarah B. White

Sarah B. White, MD, MS, FSIR, FCIRSE

Professor of Radiology and Surgical Oncology
Vice Chair, Radiology Research
Associate Dean/Assistant Provost, Faculty Affairs
Senior Medical Director, Programmatic Excellence
Department of Radiology, Division of Vascular & Interventional Radiology
Medical College of Wisconsin
Milwaukee, Wisconsin

Mark Yarchoan

Mark Yarchoan, MD

Associate Professor of Medical Oncology
Division of GI Malignancies
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Disclosure

Primary Author

Richard S. Finn, MD

Professor
Department of Medicine
Division of Hematology/Oncology
UCLA David Geffen School of Medicine
Medical Director, Clinical Research Unit
Director, Signal Transduction and Therapeutics Program
University of California, Los Angeles
Los Angeles, California

Richard S. Finn, MD: consultant/advisor/speaker: AstraZeneca, Bayer, Bristol Myers Squibb, CStone, Eisai, Exelixis, Lilly, Merck, Pfizer, Roche/Genentech.

Sarah B. White, MD, MS, FSIR, FCIRSE

Professor of Radiology and Surgical Oncology
Vice Chair, Radiology Research
Associate Dean/Assistant Provost, Faculty Affairs
Senior Medical Director, Programmatic Excellence
Department of Radiology, Division of Vascular & Interventional Radiology
Medical College of Wisconsin
Milwaukee, Wisconsin

Sarah B. White, MD, MS, FSIR, FCIRSE: consultant/advisor/speaker: AstraZeneca, Cook, Eisai, Medtronic, Penumbra, TriSalus.

Mark Yarchoan, MD

Associate Professor of Medical Oncology
Division of GI Malignancies
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Mark Yarchoan, MD: consultant/advisor/speaker: AstraZeneca, Exelixis, Genentech, Lantheus; researcher (paid to institution): Bristol Myers Squibb, Incyte; owner: Adventris.